Device Trial Radar · NCT06514196
Post- Approval Hintermann Series H® Study 1
Last checked: Nov 20, 2026Latest source record: Jul 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
298
Planned (sponsor's estimate)
Start
Jun 18, 2020
Primary completion
Nov 30, 2024
Study completion Jan 20, 2025
Sponsor
- Lead sponsor
- DT MedTech, LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 23, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The H3 TAR device received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) on June 4, 2019, and as a condition of that approval, this study is being conducted to provide long-term safety and effectiveness of the H3 TAR System among patients included in the Primary Safety and Effectiveness (PSE) Cohort (P1600361). This will be a Prospective, single-center, single arm study.
Conditions
- Ankle Osteoarthritis
- Post-Traumatic Osteoarthritis of Ankle
- Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Interventions
Hintermann Series H3 Total Ankle Replacement SystemDevice
The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AOFAS Score MeasurementTime frame: 10 Years
- Survivorship MeasurementTime frame: 10 Years
- Serious device-related adverse event MeasurementTime frame: 10 Years
3 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kantonsspital Baselland
Bruderholz, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.